Age-related alterations in cyclic nucleotide phosphodiesterase activity in dystrophic mouse leg muscle.
Previous reports have described both increased and decreased cyclic nucleotide phosphodiesterase (PDE) activity in dystrophic muscle. Total PDE activity was measured in hind leg muscle from a mouse model of Duchenne muscular dystrophy (mdx) and a genetic control strain at 5, 8, 10, and 15 weeks of age. Total PDE activity declined in fractions isolated from mdx muscle over this time period, but was stable in fractions from control mice. Compared with age-matched controls, younger mdx muscle had higher cAMP and cGMP PDE activity. However, at 15 weeks, fractions from both strains had similar cGMP PDE activity and mdx fractions had lower cAMP PDE activity than controls. Particulate fractions from mdx muscle showed an age-related decline in sensitivity to the PDE4 inhibitor RO 20-1724. A similar loss of sensitivity to the PDE2 inhibitor erythro-9-(2-hydroxyl-3-nonyl)-adenine (EHNA) was seen in a particulate fraction from mdx muscle and to a lesser degree in control muscle. These results suggest that the earlier disagreement regarding altered cyclic nucleotide metabolism in dystrophic muscle may be due to changes with age in PDE activity of dystrophic tissue. The age-related decline in particulate PDE activity seen in dystrophic muscle appears to be isozyme-specific and not due to a generalized decrease in total PDE activity.
Bloom
Timothy J
TJ
Department of Pharmaceutical Sciences, Campbell University School of Pharmacy, Buies Creek, NC 27506, USA. bloom@campbell.edu
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000378:metabolism*; D000375:Aging / Q000378:metabolism*; D000818:Animals; D005260:Female; D006614:Hindlimb; D008297:Male; D051379:Mice; D018101:Mice, Inbred mdx; D018482:Muscle, Skeletal / Q000201:enzymology*; D020388:Muscular Dystrophy, Duchenne; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology
D010726:Phosphodiesterase Inhibitors; D015105:3',5'-Cyclic-AMP Phosphodiesterases